Table 4.
Clinical relevance of low-penetrance breast cancer susceptibility genes
Population frequency | Hazard ratio (95% C.I) | Population attributable risk (PAR) | |
---|---|---|---|
TGFBR1*6A | 0.5% homozygotes | O.R. 2.69 (1.54–4.68) | 4.9% (2.7%–7.2%) of all breast cancers |
14.1% heterozygotes | O.R. 1.23 (1.06–1.43) | ||
CHEK2 | 0.5% heterozgotes | O.R. 1.5 (1.2–1.8) | Less than 0.5% of all breast cancers |
J Clin Onc 57, 23:7743-7743; Am J Hum Genet 2004, 74:1175-82; Clin Cancer Res 2006, 12:4832-4835.